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This study examines trends and geographical differences in total and live birth prevalence of trisomies 21, 18 and 13
with regard to increasing maternal age and prenatal diagnosis in Europe. Twenty-one population-based EUROCAT registries
covering 6.1 million births between 1990 and 2009 participated. Trisomy cases included live births, fetal deaths from
20 weeks gestational age and terminations of pregnancy for fetal anomaly. We present correction to 20 weeks gestational
age (ie, correcting early terminations for the probability of fetal survival to 20 weeks) to allow for artefactual screening-related
differences in total prevalence. Poisson regression was used. The proportion of births in the population to mothers aged
35þ years in the participating registries increased from 13% in 1990 to 19% in 2009. Total prevalence per 10000
births was 22.0 (95% CI 21.7–22.4) for trisomy 21, 5.0 (95% CI 4.8–5.1) for trisomy 18 and 2.0 (95% CI 1.9–2.2) for
trisomy 13; live birth prevalence was 11.2 (95% CI 10.9–11.5) for trisomy 21, 1.04 (95% CI 0.96–1.12) for trisomy 18 and
0.48 (95% CI 0.43–0.54) for trisomy 13. There was an increase in total and total corrected prevalence of all three trisomies
over time, mainly explained by increasing maternal age. Live birth prevalence remained stable over time. For trisomy 21,
there was a three-fold variation in live birth prevalence between countries. The rise in maternal age has led to an increase
in the number of trisomy-affected pregnancies in Europe. Live birth prevalence has remained stable overall. Differences in
prenatal screening and termination between countries lead to wide variation in live birth prevalence.
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INTRODUCTION
In Europe, the average age of women giving birth has steadily
increased since the late 1970s.1 In 2009, 1 million births in the
European Union were born to mothers aged 35 years and older.2 As
chromosome autosomal trisomies are more prevalent in children
born to older mothers,3 the increase in the proportion of births to
older mothers can be expected to result in an increasing number of
affected pregnancies.
Studies of Down syndrome (trisomy 21, T21) have shown
increasing trends in affected pregnancies in various parts of the world
attributed to increasing maternal age.4–7 Prenatal screening and
subsequent termination of pregnancy for fetal anomaly (TOPFA)
counteract this effect with respect to observed trends in live birth (LB)
prevalence, although this varies between countries depending on
policy, provision and uptake of prenatal screening.8 Prenatal diagnosis
during the first and second trimester also leads to the recognition and
recording of trisomy cases that would otherwise have been lost as
spontaneous abortions, and it has been suggested that this, as well as
increasing maternal age, may explain some of the increase in overall
numbers of trisomy cases diagnosed.9 Stillbirths and late fetal deaths
(FD) with chromosomal anomalies are often not included in studies,
and estimates made of in utero survival from study cohorts have not
been validated with recent population data. The last evaluations of
T21 LB trends in Europe included cases born in 1999/2000.10,11 Little
information is available in Europe on trends of Patau syndrome
(trisomy 13, T13) or Edward syndrome (trisomy 18, T18).
EUROCAT (European Surveillance of Congenital Anomalies) is a
network of population-based registries established in 1979 to conduct
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epidemiological surveillance of congenital anomalies in Europe.
In this paper, we examine trends in the total prevalence of T21,
T18 and T13 in the period 1990 to 2009; examine whether these
trends are explained by increasing maternal age or by earlier diagnosis
during pregnancy or both; describe trends in LB prevalence; examine
the extent of geographic differences within Europe in LB prevalence
and its explanation in terms of the maternal age profile and termina-
tion rate; describe late FD rates; and assess differences between
countries in the types of screening or diagnostic test that led to a
diagnosis of T21.
METHODS
EUROCAT currently has 41 member registries in 20 countries covering 31% of
all births in the European Union.12 Information on member registries and
their methods of case ascertainment are available.13,14 Each registry sends an
anonymised uniformly coded data set to EUROCAT Central Registry
containing information on cases of congenital anomaly registered in the
local population. Cases include LB, stillbirths and late FD from 20 weeks
gestational age (GA), and TOPFA at any gestation. The standardised data
set allows diagnosis of up to nine syndromes or malformations for each case
coded according to the International Classification of Diseases with British
Paediatric Association extension code (ICD9/BPA or ICD10/BPA).
The criteria for including registries in this study were maternal age recorded
forZ80% of all births in the registry population andZ80% ascertainment of
Down syndrome (DS) according to an adapted version of the DS Data Quality
Indicator15 for 2005–2009. This DS Data Quality Indicator calculates the ratio
of observed to expected DS for each registry based on maternal age profile,
external standard maternal age-specific rates and fetal survival correction
factors to 20 weeks GA (see Appendix). The final study population consisted of
21 registries in 12 countries covering 6.12 million births, 1990–2009. The DS
Data Quality Indicator for all included registries and all years combined
was 1.04%.
Cases of T13 (ICD10 codes: Q914–Q917, ICD9 code: 7581) T18 (ICD10
codes: Q910–Q913, ICD9 code: 7582) and T21 (ICD10 codes: Q90, ICD9 code:
7580) born between 1990 and 2009 were extracted from the central database in
August 2011. This study did not distinguish between trisomy, translocation
and mosaic. Although most of the registries indicated that they consult or
receive direct notification of all T21 cases from cytogenetic laboratories in
their region, some registries identified potential problems beyond their control
hence some cases may be missed. Barcelona (Spain) and East Midlands and
South Yorkshire (UK) have notification from some but not all of the
cytogenetic labs in their region. Wielkopolska (Poland) has complete informa-
tion on LB cases, but TOPFA cases are missed as the registry does not register
TOPFA. Norway receives cases through the medical birth notification form
from delivery units and neonatal intensive care units and misses about 20% of
cases.6 In Saxony Anhalt (Germany), Cork and Kerry (Ireland) and South East
Ireland case finding was mainly via obstetric or pediatric records.
Maternal age was recorded for over 99% of the birth population between
1990 and 2009, range 98.4–100%. Maternal age was not recorded for 1% of
trisomy cases, and these cases were excluded from the study.
Information on the first screening (ultrasound, serum, combined screening)
or diagnostic test (amniocentesis or chorionic villus sampling) indicating or
leading to a diagnosis of T21 was restricted to the years 2005–2009, as 2005
was the first year this information was routinely recorded by EUROCAT.
Statistical analysis
Total prevalence was calculated as:
LBþ FDþTOPFA . . . with . . . trisomy
total LBþ Stillbirths 10 000
LB prevalence per 10 000 births was calculated as
LB . . . with . . . trisomy
totalLB
10 000
‘Perinatal mortality’ was defined as (FDþ first-week death) with trisomy/
LBþ FD with trisomy.
The ‘perinatal mortality’ rate was calculated as:
FDþ 1stweekdeaths . . . with . . . trisomy
totalLBþ Stillbirths 10 000
Weights representing the probability of fetal survival to 20 weeks GA were
applied to each TOPFA case based on GA at TOPFA to correct for artefactual
screening-related differences in total prevalence (Appendix).
Total corrected prevalence was calculated as:
LBþ FDþTOPFA corrected to 20 weeks GA with trisomy
totalLBþ Stillbirths 10000
Statistical analysis was conducted using STATA version 9.0 (StataCorp LP,
College Station, TX, USA). Maternal age was categorized into six age bands
(o20, 20–24, 25–29, 30–34, 35–39, 40þ years) and entered as a categorical
variable in all models. Year of birth was entered as both a categorical variable
(1990–1994, 1995–1999, 2000–2004 and 2005–2009) and a continuous
variable. A Poisson regression model was used to assess trends over time with
year of birth entered as a linear term and to examine the effect of adjusting for
country, maternal age and correction for fetal survival to 20 weeks GA on these
trends. The Poisson model presented prevalence rate ratio (PRR) estimates and
95% confidence intervals (CI) relative to the maternal age baseline group
(mothers 25-29 years) or baseline country (Austria) or year of birth (1990).
Austria was selected as the baseline country, as its maternal age distribution
approximated the average maternal age distribution for all countries
combined.
RESULTS
Trends over time in maternal age distribution among all births in
registry population
The proportion of births to older mothers (35þ years) in EUROCAT
registries increased steadily from 13% in 1990 to 19% in 2009. The
proportion of older mothers varied by country and increased in
2000–2009 compared with 1990–1999 in all countries except Malta
and Poland (Table 1).
Maternal age-specific rates
Figure 1 shows the total corrected prevalence for each trisomy by six
maternal age groups. The PRRs of T21, T18 and T13 in mothers 40þ
years compared with mothers aged 25–29 years were 17.3 (95% CI
16.3–18.4), 18.9 (95% CI 16.8–21.3) and 10.2 (95% CI 8.3–12.4),
respectively. The PRRs of T21, T18 and T13 in mothers 35–39 years
compared with mothers aged 25–29 years were 5.5 (95% CI 5.2–5.8),
4.4 (95% CI 3.9–4.9) and 4.1 (95% CI 3.4–4.8), respectively.
Pregnancy outcome and perinatal mortality
Pregnancy outcomes for each of the trisomies are shown in Table 2.
TOPFA were more common for T18 (71%) and T13 (71%) than T21
(47%) and these proportions varied greatly by country (Table 2).
Approximately one-third of TOPFA for all three trisomies (28% of
T21, 34% of T18 and 38% of T13 cases) were at 20 weeks GA or later.
A total of 2% of T21 LB cases died before 1 week of age, compared
with 45% of T18 LB cases and 54% of T13 LB cases (data not shown).
Perinatal mortality associated with T18 (58%) and T13 (58%) was
almost 10 times the perinatal mortality associated with T21 (6%). The
perinatal mortality rate per 10 000 births in the population was 0.7 for
T21, 0.8 for T18 and 0.3 for T13.
There was a significant difference in the proportion of FD among
births (LB and FD) for T21 cases by maternal age (Po0.01). Younger
mothers (o20 years) had double the proportion of FDs among T21
births compared with mothers in other age groups. The proportion
of FDs among T18 and T13 cases did not differ significantly by
maternal age.
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Trend over time in total and LB prevalence of trisomies 21, 13, 18
Between 1990 and 2009, the total and LB prevalence of T21 was 22.0
(95% CI 21.7–22.4) and 11.2 (95% CI 10.9–11.5) per 10 000 births.
The total and LB prevalence of T18 was 5.0 (95% CI 4.8–5.1) and 1.04
(95% CI 0.96–1.12) per 10 000 births. The total and LB prevalence of
T13 was 2.0 (95% CI 1.9–2.2) and 0.48 (95% CI 0.43–0.54) per 10 000
births. There was a significantly increasing trend in the unadjusted
total prevalence of the three trisomies (Figure 2). The PRR in 2009
compared with 1990, adjusting for country of birth, are shown in
Table 3. Correction for fetal survival of TOPFA to 20 weeks GA made
little impact on these estimates (Table 3). Adjustment for increasing
maternal age in the populations removed any evidence of increasing
trend of T21, but there remained evidence of increasing trend in both
T18 and T13 (Table 3).
The LB prevalence remained stable for all three trisomies compared
with the baseline period (Figure 2).
Geographical variation in total corrected prevalence and LB
prevalence of Trisomy 21 from 2000 to 2009
There was geographical variation in total corrected prevalence of
T21 (Po 0.001), (Figure 3). After adjusting for the maternal age
distribution in the population, the PPR point estimates by country
were close to 1 except in France and Switzerland; France had 37%
higher corrected rates of T21 (95% CI 1.18–1.59) and Switzerland
27% (95% CI 1.06-1.53) compared with the baseline country
(Austria). In 10 of the 12 countries, over half of T21 cases occurred
in mothers 35þ years.
There was a more than three-fold variation in LB prevalence of T21
between countries with Ireland and Malta (where TOPFA is illegal
and thus not performed) having the highest LB prevalence (Figure 3).
Prenatal diagnosis and type of prenatal screening or diagnostic test
first indicating or leading to T21 diagnosis, 2005–2009
Thirteen registries in nine countries provided information on time of
diagnosis and first prenatal screening or diagnostic test for 98% of
cases from 2005 to 2009. Overall, 1598 cases (62%) were prenatally
diagnosed (PD), ranging from 9% to 21% in Ireland and the Ukraine
to over 80% in France, Spain and Switzerland. In all, 52% of T21
cases were PD in mothers o35 years and 70% were PD in mothers
35þ years, which varied by country (Figure 4).
Of the PD cases, 14% were LB, 2% were FD and 83% were TOPFA.
The proportion of PD T21 cases resulting in TOPFA wasZ80% in all
counties where TOPFA is practiced except Ukraine, (range 58% in
Ukraine to 97% in Spain).
Of the PD cases, T21 was first suspected following ultrasound
examination in just under a third of cases (range from 7–9% in
Denmark and Ireland to 46% in France), (Figure 5). The ultrasound
test was performed o14 weeks GA in 58% of these cases (458% in
Denmark, France, Span, Switzerland and UK). In all, 16% of cases
were diagnosed following a first positive indication from serum/
combined screening, (range from 0% in Germany, Ireland, Spain and
Ukraine to 49% in Switzerland and 60% in Denmark), (Figure 5).
A total of 16% of cases were diagnosed by chorionic villus sampling/
amniocentesis not preceded by any screening test, ranging from the
minority of cases in most countries, to 28% of PD cases in Austria,
43% of PD in Germany and 59% of PD in Spain, (Figure 5). Overall,
of the 16% of PD cases diagnosed by invasive tests not preceded by
ultrasound or biochemical screening tests, 78% were performed in
mothers 35þ years, range from 67% in Ireland to 100% in Denmark
and France.
DISCUSSION
The rise in average maternal age in Europe over time has brought
with it an increase in the number of pregnancies affected by trisomies
21, 18 and 13. However, the increasingly widespread practice of
prenatal screening and termination of pregnancy has, on average,
counteracted the effect of maternal age and resulted in a relatively
stable LB prevalence of the major trisomies since 1990 in the
European population studied. This is consistent with other studies
in many areas of the world reporting no increasing trends over time
in LB prevalence of the major trisomies,16,17 whereas total prevalence
has been increasing.5,7,18
There are significant and changing geographic inequalities in both
total and LB prevalence of T21. The 2.7-fold variation in total
prevalence between countries from 2000 to 2009 is mainly due to the
Table 1 The number of EUROCAT registries, proportion of birth
population covered by EUROCAT in 2007, number of births and
proportion of older mothers, per country, 1990–2009
Countrya:
Registry
No.
Regi-
stries
No. of
births
1990–
2009 c
Coverage
of national
birth
population
in 2007 (%)
Proportion
of all births
to mothers
35þ years
1990–1999
Proportion of
all births to
mothers 35þ
years 2000–
2009 (% 40þ )
Ukraine 1 146 055 6 – 7.4 (1.4)
Poland:
Wielkopolska
1 357 971 10 8.7 8.6 (1.6)
Malta 1 89913 100 14.2 12.2 (2.2)
Germanyb 2 324 004 3 9.2 13.6 (2.1)
Austria: Styria 1 229 506 13 8.3 15.6 (2.6)
Denmark: Odense 1 111 754 9 10.6 16.5 (2.3)
Norway 1 587 489 100 13.7 17.1 (2.4)
UKb 5 2 116 962 26 13.2 17.3 (2.9)
Franceb 2 854 202 6 17.9 24.4 (5.1)
Irelandb 3 602 551 63 19.6 24.4 (3.8)
Switzerland: Vaud 1 150 775 10 13.6 25.6 (4.7)
Spainb 2 546 575 7 17.9 30.4 (4.4)
Total 21 6 117 757 13 15.5 18.2 (2.5)
aCountries are ordered by % mothers 35þ years in 2000–2009.
bCountries with more than one EUROCAT registry: France (Paris, Strasbourg); Germany (Mainz,
Saxony Anhalt); Ireland (Cork and Kerry, Dublin, South East); Spain (Barcelona, Basque
Country); UK (East Midlands and South Yorkshire, Northern England, Thames Valley, Wales,
Wessex).
cData covers 1990–2009 for all registries except: France Strasbourg 1990–2005; Germany
Saxony Anhalt 1991–2009; Ireland, Cork and Kerry 1996–2005, 2008, South East
1997–2008; Norway 1999–2008; Poland 1999–2008; Spain, Barcelona 1992–2007, Basque
Country 1990–2008; Ukraine 2005–2009; UK, East Midlands and South Yorkshire
1998–2009, Northern England 2000–2009, Thames Valley 1995–2009, Wales 1998–2009
and Wessex 1994–2009.
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Figure 1 Total corrected prevalence per 10 000 births (log scale) of
trisomies 21, 18 and 13 by maternal age, 1990–2009, 12 European
countries.
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large variation in maternal age profile of European countries and
regions within countries. Geographical variation in LB prevalence of
T21 due to the differences in TOPFA rate between countries is even
greater. There is a more than three-fold higher LB prevalence of T21
in countries where TOPFA is illegal (Ireland and Malta)8 than in other
countries. Individual countries may also differ in their LB prevalence
trends, and country-specific LB prevalence trends can be found on the
EUROCAT website, updated each year.19
Because of the earlier detection of trisomies prenatally, more cases
are now being diagnosed that would otherwise not have survived to
birth. This is particularly true of trisomies 18 and 13, which have high
natural early fetal loss rates. This problem has long been recognized
for epidemiological surveillance, and standard correction factors have
been employed for T21 to correct terminations of pregnancy for
probability of survival to LB.20,21 We instead corrected early
terminations of pregnancy for probability of survival to 20 weeks
GA, essentially calculating prevalence at 20 weeks GA in the absence
of intervention. This meant we could compare total prevalence trends
including all diagnosed cases to corrected total prevalence trends. We
find however that such correction for fetal survival has little impact
Table 2 The total number of casesa with trisomies 21, 18 and 13 and the proportion by pregnancy outcome by country, 1990–2009
Trisomy 21 Trisomy 18 Trisomy 13
Country
Total
cases (n)
LB
(%)
FD
(%)
TOPFA
(%)
% FD of
LBþ FD
Total
cases (n)
LB
(%)
FD
(%)
TOPFA
(%)
% FD of
LBþ FD
Total
cases (n)
LB
(%)
FD
(%)
TOPFA
(%)
% FD of
LBþ FD
Austria: Styria 381 51.4 2.1 46.5 3.9 78 21.8 5.1 73.1 19.1 57 28.1 7.0 64.9 20.0
Denmark: Odense 209 47.4 5.3 47.4 10.0 47 25.5 10.6 63.8 29.4 17 17.7 5.9 76.5 25.0
France 2690 25.2 1.7 73.1 6.2 737 7.1 4.9 88.1 40.9 266 7.5 3.4 89.1 31.0
Germany 559 50.5 2.9 46.7 5.4 107 18.7 11.2 69.4 37.5 50 16.0 10.0 74.0 38.5
Ireland 1369 94.7 5.1 0.2 5.1 225 64.4 35.6 0 35.6 118 78.8 21.2 0 21.2
Malta 166 99.4 0.6 0 0.6 28 96.4 3.6 0 3.6 4 100.0 0 0 0.0
Norway 1043 70.2 1.7 28.1 2.4 235 33.2 8.9 57.9 21.2 102 33.3 2.9 63.7 8.1
Poland:
Wielkopolska
515 99.6 0.4 0 0.4 55 94.6 5.5 0 5.5 19 84.2 15.8 0 15.8
Spain 1357 32.6 0.8 66.6 2.4 290 12.4 3.1 84.5 20.0 99 14.1 2.0 83.8 12.5
Switzerland: Vaud 437 23.3 1.6 75.1 6.4 86 7.0 5.8 87.2 45.5 39 15.4 0 84.6 0.0
Ukraine 195 86.7 1.5 11.8 1.7 10 40.0 0 60.0 0.0 10 40.0 10.0 50.0 20.0
UK 4550 48.8 3.4 49.8 6.7 1135 16.0 7.8 76.1 32.8 466 16.3 4.1 79.6 20.0
Total 13471 50.5 2.6 46.9 4.8 3033 20.8 8.7 70.5 29.6 1247 23.6 5.8 70.7 19.7
Abbreviations: FD, fetal deaths from 20 weeks; LB, live birth; MA, maternal age; TOPFA, termination of pregnancy for fetal anomaly (TOPFA is not legal in Ireland and Malta; and not practised in
Poland).
Total¼LBþ FDþTOPFA
aStudy exclusions due to unknown MA: 154 cases of T21 (4 Austria, 9 France, 28 Germany, 6 Ireland, 2 Malta, 28 Poland, 21 Spain and 56 UK); 25 cases of T18 (1 France, 7 Germany,
2 Ireland, 1 Malta, 2 Poland, 5 Spain and 7 UK); 10 cases of T13 (2 France, 2 Germany, 1 Norway, 4 Spain and 1 UK).
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Figure 2 Total and LB prevalence per 10000 births of trisomy 21, 18 and 13 in 12 European countries, 1990-2009.
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on total prevalence rates, especially for T21, and is certainly a much
lesser explanation of temporal and geographic variation than
maternal age.
An average late fetal loss rate of 25–30% for T21 is widely cited,20-23
which is much higher than the EUROCAT average late fetal loss rate
of 5%. Although some level of under ascertainment of late FD with
T21 is possible in EUROCAT regions, especially for cases where there
was no prenatal diagnosis, the close correspondence of EUROCAT
rates to expected rates suggests high ascertainment. It is possible
instead that prenatal diagnosis is selectively picking up T21 cases with
serious heart or other structural anomalies with lower expected late
fetal survival, thus depressing late FD proportions among those not
PD. It is also possible that late miscarriage rates reported in the
literature calculated from prenatal diagnosis series have selectively
included pregnancies examined owing to signs of poor fetal growth,
and/or that T21 babies born with severe heart anomalies were
previously less likely to be registered as live births. EUROCAT late
fetal loss rates for T18 and T13 are high and vary between European
populations, but are also lower than estimates from prenatal diagnosis
cohorts.17 Further research on late FD for trisomies is needed.
Meanwhile, we recommend correcting total prevalence to 20 weeks
GA instead of to LB, to avoid the assumption that late fetal loss for
trisomies is constant across populations.
The perinatal mortality rate due to the three trisomies combined
was 1.9 per 10 000 births, of which nearly two-thirds was T18 and
T13, which despite their low prevalence had high case fatality.
We found evidence of some differences in total prevalence of the
three trisomies over time and between countries that could not be
completely explained by differing maternal age profiles or changes in
GA at detection. There was evidence of an increasing trend in the
adjusted total prevalence of T13 and T18 (but not T21) over time,
which may relate to improvements in diagnosis (prenatal and/or
postnatal) over time; and evidence that France and Switzerland
had higher T21 total prevalence than others, requiring further
investigation.
The EUROCAT total prevalence rates of T18 and T13 are broadly
comparable with other studies,18,24-27 but exact comparison is
difficult, as most studies concern LB rates and are from populations
with different maternal age profiles.
Ultrasound and biochemical screening have been introduced on a
population-wide basis in many European countries. There is no policy
for prenatal screening of T21 in Ireland or Malta.28 Screening policy
and uptake varies considerably8 as demonstrated in our data by both
prenatal diagnosis rates and types of screening test performed. The
distinction between ultrasound and combined screening in our data
may be blurred as some ultrasounds might have been performed as
part of an intended combined test but where the biochemical
Table 3 The unadjusted and adjusted prevalence rate ratio (PRR) of
each trisomy in 2009 relative to 1990, 12 European countries
PRR adjusted
for country
PRR adjusted
for country and
correction to
20 weeks GA
PRR adjusted
for country, MA
and correction
to 20 weeks GA
Trisomy 21 1.48 (1.38–1.58) 1.46 (1.36–1.56) 1.00 (0.93–1.07)
Trisomy 18 2.17 (1.87–2.51) 1.98 (1.70–2.31) 1.38 (1.18–1.61)
Trisomy 13 1.80 (1.43–2.26) 1.69 (1.34–2.14) 1.26 (1.00–1.60)
Abbreviations: FD, fetal deaths from 20 weeks; LB, live birth; MA, maternal age; PRR,
prevalence rate ratio.
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screening was not carried out. According to our data, significant
numbers of women in some countries are having an invasive test
(amniocentesis or CVS) solely on indication of maternal age.
Paradoxically, maternal age has increased over the years that
screening methods have been developed to include younger
maternal ages, and 10 of 12 countries report a majority of T21
cases among older mothers.
This study covers almost 13% of all births in the 12 European
countries represented in 2007. The regions are representative of
European statistics2 in terms of maternal age, especially since year
2000, but may differ in terms of prenatal screening and TOPFA from
other regions in these countries. Some caution should therefore be
exercised in interpretation of national differences. Continued
surveillance of trisomy 13, 18 and 21 is important for assessing the
impact of delayed childbearing, evaluating screening programmes and
providing health care. Prevalence of T21, T18 and T13 has increased
over time, largely due to the increasing number of older mothers
giving birth. However, owing to the increased use of prenatal
screening and subsequent terminations, the LB prevalence of these
trisomies has remained relatively constant.
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Figure 5 Proportion of trisomy 21 cases prenatally diagnosed by type of
prenatal test first indicating or leading to prenatal diagnosis, 9 European
countries, 2005–2009. US, Ultrasound CVS/ amnio, Chorionic villus
sampling or amniocentesis. *Ireland (Cork and Kerry, South East Ireland),
UK (Northern England, Thames Valley, Wales, Wessex).
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APPENDIX
Fetal Survival Correction Factorsa – Probability of surviving up to
20 weeks gestational age applied to each TOPFA case by trisomy
Gestation (weeks)
10 11 12 13 14 15 16 17 18 19 20
Trisomy 21 0.89 0.91 0.92 0.93 0.97 0.97 0.98 0.98 0.99 1.00 1.00
Trisomy 18 0.73 0.74 0.75 0.76 0.81 0.86 0.87 0.93 0.94 0.96 1.00
Trisomy 13 0.77 0.79 0.80 0.83 0.85 0.85 0.88 0.90 0.90 0.95 1.00
aBased on publications by Savva et al29 and Morris and Savva17. Savva et al29 analyzed fetal
loss in 5177 PD pregnancies with trisomy 21 according to gestational age. Data from the
survival curve in Figure 1 in the paper (personal communication) provided the probability of
loss at each gestational age. Similarly, Morris and Savva17 analyzed fetal loss in 198 PD
pregnancies with trisomy 13 and 538 pregnancies with trisomy 18 according to gestational
age. Data from the survival curves in Figure 1 in the paper provided the probabilities of loss of
pregnancies with trisomy 13 and 18 at each gestational age from 12 weeks of gestational age.
Estimates for the fetal losses from 10 and 11 weeks gestational age were obtained by
assuming the same fetal loss rates as observed in Down syndrome.
The risk of fetal loss before 20 weeks gestation given the pregnancy
was terminated at X weeks gestation is estimated by the probability of
fetal loss at X weeks divided by the probability of fetal loss at 20 weeks
gestation. This risk is the survival correction weight given in Table 1.
These weights are then used to adjust the number of terminations
reported at each gestational age to predict the number that would
have survived to 20 weeks gestation.
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